Comparative impacts and cost-effectiveness of tuberculosis active case-finding strategies in prisons in Brazil, Colombia, and Peru: a mathematical modeling study

Yiran E Liu, PhD[1,2*], José Victor Bortolotto Bampi, MD[3], Ronan F Arthur, PhD[2], Argita D Salindri, PhD[2], Caroline Busatto, PhD[4], Pedro Avedillo Jiménez, MD[5], Daniele Maria Pelissari, PhD[4], Fernanda Dockhorn Costa Johansen, MD[4], Robert Arana-Narvaez, MD[6], Alvaro Fernando Moreno Roca, BS[6], Wilfredo Santos Solís Tupes, MD[6], Esther Mori Jiu, MD[6], Christian Alfredo Moreno Roca, BSN[6], Erika Albertina Abregú Contreras, BSN[6], Valentina Antonieta Alarcón Guizado, MD[6], Julián Trujillo Trujillo, MS[7], Belkys Marcelino, MD[5,8], Mónica Alonso Gonzalez, MD[5], Mayra Cecilia Córdova Ayllon, BS[9], Ted Cohen, DPH[10], Moises A Huaman, MD[11], Jeremy D Goldhaber-Fiebert, PhD[12,13], Julio Croda, MD[3,10,14], Jason R Andrews, MD[2*]

[1] Department of Epidemiology and Population Health, Stanford University, Stanford, California, USA.
[2] Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University, Stanford, California, USA.
[3] Federal University of Mato Grosso do Sul, Campo Grande, Brazil.
[4] National Tuberculosis Program, Ministry of Health, Brasília, Brazil.
[5] Pan American Health Organization, Communicable Diseases Prevention, Control and Elimination, Washington, DC, USA.
[6] Dirección de Prevención y Control de la Tuberculosis, Ministerio de Salud, Lima, Perú.
[7] Ministerio de Salud y Protección Social, Subdirección de Enfermedades Transmisibles, Bogotá, Colombia.
[8] School of Public Health, Universidad Autónoma de Santo Domingo, Santo Domingo, Dominican Republic.
[9] Instituto Penitenciário Nacional, Lima, Peru.
[10] Department of Epidemiology of Microbial Diseases, School of Public Health, Yale University, New Haven, Connecticut, USA.
[11] Division of Infectious Diseases, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
[12] Department of Health Policy, Stanford University School of Medicine, Stanford, California, USA.
[13] Center for Health Policy, Freeman Spogli Institute, Stanford University, Stanford, California, USA.
[14] Fiocruz Mato Grosso do Sul, Campo Grande, Brazil.

[*] Co-corresponding authors

ABSTRACT

Background

Incarceration is a leading driver of tuberculosis in Latin America. Active case-finding in prisons may reduce population-wide tuberculosis burden, but optimal strategies and cost-effectiveness remain uncertain.

Methods and findings

Using dynamic transmission models calibrated to Brazil, Colombia, and Peru, we simulated annual or biannual (twice-yearly) prison-wide screening, alone or combined with entry and exit screening from 2026-2035. We evaluated four algorithms: 1) symptom screening, 2) chest X-ray with computer-aided detection (CXR-CAD), 3) symptoms and CXR-CAD (follow-up testing if either is positive) and 4) GeneXpert Ultra with pooled sputum. Individuals screening positive then received individual Xpert. We projected impacts on within-prison and population-level tuberculosis incidence in 2035, along with discounted costs (2023 USD) and disability-adjusted life years (DALYs). Model projections showed that combined entry, exit, and biannual screening with CXR-CAD was highly impactful and cost-effective across countries, reducing tuberculosis incidence by 62-87% in prisons and 18-28% population-wide. Compared to only biannual CXR-CAD (the next best strategy), the incremental cost per DALY averted of adding entry and exit screening was $2984 (Brazil), $2925 (Colombia), and $645 (Peru). Adding symptom screening to CXR-CAD marginally increased benefit and was only cost-effective in Peru's higher-incidence prisons. Biannual screening alone remained cost-effective at prison incidence levels well below national averages. In settings without CXR-CAD, pooled Xpert was an impactful, cost-effective alternative.

Conclusions

These modeling results support immediate national-level adoption of prison-wide tuberculosis screening twice-yearly and at entry and exit. Screening should begin with available methods while building capacity for CXR-CAD, the most cost-effective algorithm.

AUTHOR SUMMARY

Why was this study done?

- In Latin America, rising incarceration has fueled the tuberculosis epidemic, with extremely high infection rates among people deprived of liberty. These effects extend beyond prison walls, driving tuberculosis spread in outside communities.
- Interventions targeted to prisons may have an outsized impact on reducing tuberculosis in the broader population.
- The World Health Organization strongly recommends systematic screening for tuberculosis in prisons, but there is little evidence on how often to screen, which methods to use, and whether these approaches are cost-effective across different country contexts.

What did the researchers do and find?

- We developed mathematical models using data from Brazil, Colombia, and Peru to simulate different prison-based tuberculosis screening strategies and project their health impacts and costs.
- We compared prison-wide screening once or twice a year, screening at prison entry or exit, and combinations of these approaches. We also compared different screening methods using symptoms, chest X-ray with computer-aided detection (CXR-CAD), or pooled molecular testing (GeneXpert Ultra).
- The models projected that combining entry, exit, and twice-yearly prison-wide screening with CXR-CAD would be highly impactful and cost-effective in all three countries. This strategy could substantially reduce tuberculosis in prisons and in the general population.
- Twice-yearly prison-wide screening remained cost-effective even in prisons with much lower tuberculosis rates than national averages.
- CXR-CAD was the optimal screening method, but pooled molecular testing was also impactful and cost-effective where CXR-CAD was not available.

Implications of all the available evidence

- Systematic screening in prisons, twice-yearly and at entry and exit, is projected to be highly impactful and cost-effective across different settings in Latin America.
- These findings support urgent adoption of intensive prison-based tuberculosis screening throughout the region, starting with the best available diagnostic tools while investing in CXR-CAD.

INTRODUCTION

Tuberculosis persists as a leading global health threat, with an estimated 10.8 million people falling ill and 1.25 million people dying from the disease in 2023[1]. People deprived of liberty (PDL) experience substantially elevated risk of tuberculosis due to prison conditions like overcrowding, poor ventilation, malnutrition, and limited access to medical care[2]. Timely diagnosis and treatment are an essential component of tuberculosis control in prisons, but studies estimate that only about half of PDL with tuberculosis globally are diagnosed[3].

In Latin America, tuberculosis incidence and deaths have increased since 2015, and the worsening tuberculosis epidemic is increasingly driven by prisons[2]. Our recent modeling study estimated that, following decades of rising incarceration rates, 27% of new cases in the region were attributable to incarceration[4]. Interventions to address tuberculosis in prisons may have an outsized impact on the population-wide tuberculosis epidemic in Latin America.

Tuberculosis active case-finding, or systematic screening, may improve early detection and reduce transmission in prisons[5]. Since 2021, the World Health Organization (WHO) has strongly recommended systematic screening in prisons, at minimum annually and upon entry and exit[6]. However, the guidelines cite a "very low certainty of evidence" and highlight the need for more research on the effectiveness and cost-effectiveness of different strategies. Recent empirical studies in prisons have demonstrated high yield from strategies using chest x-ray with computer-automated detection (CXR-CAD) or molecular rapid testing (i.e. GeneXpert) with sputum pooling[7-10]. However, their broader impact and cost-effectiveness remain uncertain, especially across settings with varying tuberculosis epidemiology and carceral characteristics[6]. Moreover, the WHO has described biannual (twice-yearly) mass screening in prisons as "ideal," but lacking economic evidence, cited resource constraints as potential barriers to sustained implementation[11]. Existing modeling studies in the region offer limited guidance: of two prior studies, both were conducted in Brazil only and used subnational data, and neither assessed cost-effectiveness nor modeled screening more than once per year[12,13].

In this study, we utilize a compartmental dynamic transmission model to project the population-level impact and cost-effectiveness of tuberculosis active case-finding interventions in prisons in Brazil, Colombia, and Peru. We evaluate strategies for screening across different timepoints (i.e., entry, exit, periodic), frequencies (annual or biannual), and algorithms (symptom screening, CXR-CAD, combined symptoms and CXR-CAD, or GeneXpert Ultra with sputum pooling). All algorithms include follow-up testing with individual GeneXpert Ultra. We also perform sensitivity analyses to identify preferred strategies in settings with lower prison incidence or without access to CXR-CAD technology.

METHODS

Transmission model and key assumptions

We extended a published compartmental transmission model simulating tuberculosis and incarceration dynamics[4]. The model includes a simple representation of tuberculosis natural history for the population 15 years of age and older. Upon infection, **S**usceptible individuals transition to **E**arly latent infection, after which they activate to **I**nfectious disease or transition to **L**ate latent infection, with lower risk of active disease. Individuals in **I** transition to **R**ecovered through self-cure or diagnosis and successful treatment. Individuals in **L** and **R** can be re-infected to **E**, and individuals in **R** can relapse to **I**.

These natural history compartments are reproduced across four population strata, which individuals traverse upon incarceration, release, and re-incarceration: prison (**p**), recent history of incarceration (**r**), distant history of incarceration (**d**), and never incarcerated (**n**). The model is not stratified by age, gender/sex, or HIV. Multi-drug resistant (MDR) tuberculosis was not modeled explicitly but was accounted for by adjusting treatment outcomes and costs based on relative proportions of drug-sensitive and drug-resistant tuberculosis.

The model was separately calibrated for Brazil, Colombia, and Peru to country-specific data from 1990-2023. Data targets included prevalence of incarceration, prison admission rates, recidivism, population-wide tuberculosis notifications and incidence, and within-prison tuberculosis notifications and incidence[4]. Calibration targets for prison incidence were based on a previous study using Bayesian meta-regression modeling to estimate within-prison case-detection ratios (**Appendix**)[3]. Model fit to data is shown in **Figures S1-S2**. From 2023 on, we assume stable prison entry and release rates, with incarceration rates eventually leveling off. The elevated risk of tuberculosis in prisons is operationalized through higher effective contact rates, higher disease progression rates, and lower diagnosis rates in prisons than in the community[4]. Individuals with recent incarceration history are assumed to have similar contact rates as never incarcerated individuals, but higher disease progression rates and lower diagnosis rates[4]. The transition from recent to distant incarceration history occurs on average at seven years following release, after which rates of contact, progression, and diagnosis match those of never incarcerated individuals[12].

Interventions and scenarios

In the base-case scenario, we assume only passive diagnosis in prisons. Under passive diagnosis, people with presumptive TB undergo clinical evaluation, with a proportion receiving bacteriologic testing using smear microscopy and/or GeneXpert Ultra. A proportion of confirmed cases additionally receive culture and drug susceptibility testing (DST). Coverage of each testing method is informed by country-specific programmatic data **(Table S1)**.

We simulated prison-based active case-finding interventions, in addition to passive diagnosis, implemented from the start of 2026 through the end of 2035. We modeled systematic screening at prison entry or exit, prison-wide screening conducted annually or biannually (twice yearly), or a combination of entry, exit, and annual or biannual screening. We assume entry screening applies to individuals entering prison from the community as well as individuals transferred

between prison facilities. Screening of transferred individuals was modeled by adding a

continual rate of screening to the prison stratum; movements between prisons were not explicitly

modeled. Exit screening only applies to individuals exiting prisons to the community. Parameters

governing screening coverage, duration, linkage to care post-release, treatment completion in

prison and post-release, and costs are detailed in **Table S1**. Individuals in **E** who test false

positive and complete active treatment transition to **L**. Other false positives do not undergo any

model-based transitions.

Screening algorithms and assumptions

For each intervention, we compared four screening algorithms: 1) symptom-based, 2) CXR-CAD,

3) combined symptoms and CXR-CAD, and 4) GeneXpert Ultra MTB/RIF with pooled sputum.

We used empirical accuracy estimates from studies of active case-finding in prisons when

available. Symptom screening was based on cough of any duration, the symptom for which the

most data from prisons are available. For combined symptoms and CXR-CAD, individuals with

either symptoms or an abnormal X-ray (or both) are considered screen-positive. For sputum

pooling, samples from eight individuals are combined and tested using a single Xpert cartridge;

we assume that pooling reduces Xpert sensitivity but does not affect specificity[9]. If the pooled

test is positive, each individual sample in the pool is tested separately to identify screen-positive

individuals. Individuals who screen positive receive follow-up testing with individual GeneXpert

Ultra on a new sputum sample and clinical evaluation. Accuracy and costs of screening methods

and follow-up testing are shown in **Table 1.**

All individuals diagnosed through screening (including false positives) receive culture, DST, and

treatment. Individuals diagnosed through exit screening initiate treatment only if they are linked

to care. In any intervention, individuals who initiate but do not complete treatment are assumed

to incur half the treatment costs.

Costs and outcomes

We projected the percent reduction in prison and population tuberculosis incidence in 2035, the

last year of the intervention period, compared to the base-case scenario. Across all population

strata, we projected disability-adjusted life years (DALYs) due to tuberculosis and post-

tuberculosis sequelae[14] and estimated costs from the health system perspective, including costs

of screening, follow-up testing, diagnosis, and treatment for cases detected through passive and

active case-finding. We used a ten-year analytic horizon, accounting for lifetime DALY streams.

Costs are reported in 2023 US dollars (USD), adjusted for inflation using the World Bank GDP

deflator[15]. Costs and DALYS were standardized per 100,000 population and discounted at 3%

annually[16].

Cost parameters were sourced from costing studies conducted in the selected countries

(**Appendix**). Costs in the base-case scenario include costs of passive diagnosis and treatment.

Intervention costs include screening and treatment. Costs for each screening algorithm include

costs of equipment, consumables, and labor for screening and follow-up testing. Costs of
treatment include costs of drugs, hospitalization, directly observed treatment (DOT), and follow-
up evaluation and testing for the average patient. Treatment costs were assumed to be the same
for patients diagnosed through passive and active case-finding. We report costs relative to the
base-case scenario as the net of intervention costs and cost savings from averted cases.

For strategies on the cost-effectiveness efficiency frontier, we calculated incremental cost-
effectiveness ratios (ICERs), defined as the additional cost for each additional DALY averted
compared to the next-best non-dominated strategy[16]. Strategies were considered cost-effective if
their ICERs were within country-specific cost-effectiveness thresholds: $8602 (Brazil), $5618
(Colombia), and $5731 (Peru)[17-19] (**Appendix**).

Uncertainty and sensitivity analyses

We sampled 1000 sets of intervention parameters and cost inputs from uncertainty distributions
using Latin Hypercube sampling. These sets were randomly paired with 1000 sets of fitted model
parameters, calibrated to data targets also sampled from uncertainty distributions[4]. We repeated
the analysis for each set of parameters and inputs, generating a distribution for each outcome,
from which we report summary values (mean or median) and 95% uncertainty intervals.

We additionally performed several sensitivity analyses. First, we examined how variation in
within-prison tuberculosis incidence could affect the preferred screening strategy. We generated
scenarios with lower prison incidence by varying within-prison transmission rates, representing
variation in prison conditions (i.e. crowding, ventilation). We then conducted multinomial
logistic regression and estimated the probability that each strategy would be optimal across the
range of prison incidence levels. Second, we re-examined the efficiency frontier and preferred
strategy in a scenario without access to CXR-CAD technology, which remains the current reality
for most prisons in low- and middle-income countries. Third, we assessed how costs and health
benefits would vary with reduced screening coverage, focusing on periodic prison-wide
screening with CXR-CAD. Additional details are provided in the **Appendix**.

RESULTS

Carceral characteristics and status quo tuberculosis incidence

The median projected incarceration rate in 2026 among the population aged 15 and older was
286 per 100,000 in Colombia, 376 per 100,000 in Peru, and 476 per 100,000 in Brazil (**Figure
S3**). Carceral dynamics also varied across countries. The average duration of incarceration
ranged from 1.3 years in Brazil to 4.9 years in Peru, and the proportion entering prison with prior
incarceration history ranged from 18% in Colombia to 60% in Brazil.

In the base-case scenario without systematic screening in prisons, the model projected that by
2035, the incidence of tuberculosis in prisons would be approximately 2000 (95% UI, 1600-2700)
per 100,000 person-years in Brazil, 1500 (1000-2500) per 100,000 in Colombia, and 6100 (4100-

9600) per 100,000 in Peru (**Figure S3**). At the population level, projected tuberculosis incidence
in 2035 without screening in prisons was 33 (95% UI, 28-41) per 100,000 in Colombia, 42 (38-
47) per 100,000 in Brazil, and 105 (83-130) per 100,000 in Peru.

Intervention impacts on prison and population-wide tuberculosis incidence

Annual screening was projected to significantly reduce in-prison and population-wide
tuberculosis incidence across countries. Compared to the base-case scenario, annual screening
with CXR-CAD could reduce prison incidence in 2035 by 35.3% (95% UI, 27.9-43.8) in Brazil,
58.7% (48.4-69.4) in Colombia, and 32.3% (24.2-39.7) in Peru (**Figure 1, Table S2**). These
correspond to population-level incidence reductions of 13.8% (95% UI, 10.2-18.7) in Brazil,
11.9% (7.2-20.7) in Colombia, and 10.6% (7.4-14.2) in Peru.

Biannual (twice-yearly) screening could yield even greater impacts than annual screening.
Biannual screening with CXR-CAD was projected to reduce prison incidence in 2035 by 61.9%
(95% UI, 52.0-71.9) in Brazil, 83.1% (74.7-89.6) in Colombia, and 55.0% (45.7-63.9) in Peru
(**Figure 1, Table S2**). At the population level, biannual screening with CXR-CAD could reduce
incidence by 24.0% (95% UI, 18.1-31.2) in Brazil, 16.8% (10.4-28.4) in Colombia, and 18.1%
(12.6-24.4) in Peru. Compared to annual screening with CXR-CAD, biannual screening with
CXR-CAD averted, on average, 58% more DALYs in Brazil, 35% more DALYs in Colombia,
and 46% more DALYs in Peru (**Table 2**). Biannual screening even averted more DALYs than the
combination of entry, exit, and annual screening, highlighting the favorable effectiveness of
prison-wide screening (**Table S3**).

Combining entry, exit, and biannual screening was the most impactful strategy. Conducted with
CXR-CAD, this combination was projected to reduce prison incidence by 73.5% (95% UI, 63.6-
81.9) in Brazil, 86.5% (82.7-91.7) in Colombia, and 61.4% (52.9-69.6) in Peru (**Figure 1, Table
S2**). This amounted to population tuberculosis incidence reductions of 28.4% (95% UI, 21.6-36.5)
in Brazil, 17.8% (11.0-29.7) in Colombia, and 20.4% (14.1-27.2) in Peru.

After interventions ended, impacts were not sustained, with incidence returning to baseline levels
within five to ten years (**Figure S4**).

Comparative impacts of different screening algorithms

Algorithms involving CXR-CAD were most impactful in reducing prison and population
incidence. When used for biannual screening, CXR-CAD was projected to yield 33-58% greater
reductions in prison incidence than symptom screening across countries (**Table S2**). Projected
impacts from screening with both symptoms and CXR-CAD were slightly greater than, but
largely comparable to, those from screening with CXR-CAD alone (**Figure 1, Table S2**).

Following algorithms involving CXR-CAD, the next most impactful algorithm was GeneXpert
with sputum pooling, which yielded 20-28% greater projected reductions in prison incidence
than symptom screening when used biannually (**Table S2**).

Projected impacts of symptom screening were less than those of more sensitive algorithms but
still substantial, especially with periodic prison-wide screening. In fact, biannual symptom
screening had projected impacts comparable to those of annual screening with CXR-CAD (**Table**
2, Table S2).

Costs and cost-effectiveness of screening strategies

Table S3 reports DALYs averted, total costs, and additional costs relative to the base case
scenario for all interventions and screening algorithms evaluated. Of all screening strategies
assessed, four were on the efficiency frontier, exhibiting the greatest health benefit (i.e., averted
the most DALYs) at a given cost (**Figure 2, Table 2**). All other strategies were strictly dominated
(i.e., offer less health benefit at equivalent or higher cost) or weakly (extended) dominated (i.e.,
an alternative exists that offers better value for money) (**Table S3**).

The four non-dominated strategies on the efficiency frontier, ordered from least to most costly
and effective, were:

1) Annual screening with CXR-CAD;
2) Biannual screening with CXR-CAD;
3) Entry, exit, and biannual screening with CXR-CAD; and
4) Entry, exit, and biannual screening with symptoms and CXR-CAD.

In Brazil and Colombia, strategy 3 (entry, exit, and biannual screening with CXR-CAD) was the
optimal strategy, providing the greatest health benefit within each country's cost-effectiveness
threshold. Specifically, upgrading from biannual screening to the combination of entry, exit, and
biannual screening with CXR-CAD had an ICER of $2984 in Brazil and $2925 in Colombia
(**Table 2**). Moving from strategy 3 to 4 (i.e., screening with both symptoms and CXR-CAD
rather than CXR-CAD alone) averted few additional DALYs at much higher cost, with ICERs of
$15,416 in Brazil and $16,207 in Colombia, exceeding both countries' cost-effectiveness
thresholds.

In Peru, the ICER for moving from strategy 3 to 4 was $4158, within the cost-effectiveness
threshold, suggesting that, in the highest burden settings, the additional benefits justify the
additional costs of a slightly more sensitive but less specific screening algorithm (**Table 2**).

Of note, the combination of entry, exit, and annual screening—the current WHO
recommendation—was dominated by biannual screening in all three countries (**Figure 2, Table**
S3). In other words, countries that have implemented annual screening would get more health
benefit while spending less by increasing screening frequency to twice yearly, rather than adding
entry and exit screening.

Sensitivity analysis: varying prison incidence

We examined how the optimal strategy would vary by prison incidence, by simulating scenarios
with differing levels of within-prison transmission. Entry, exit, and biannual screening with

CXR-CAD remained the optimal strategy at prison incidence levels above approximately 1,000
per 100,000 person-years (**Figure 3, Table S4**). At extraordinarily high prison incidence levels
(>5,300 per 100,000 person-years), combining symptoms and CXR-CAD for entry, exit, and
biannual screening became the preferred strategy.

At lower prison incidence levels, less intensive strategies were optimal. Annual screening with
CXR-CAD was cost-effective at prison incidence levels greater than approximately 120 per
100,000 person-years (**Figure 3, Table S4**). Biannual screening with CXR-CAD was cost-
effective at prison incidence levels above approximately 210 per 100,000 in Brazil, 300 per
100,000 in Colombia, and 440 per 100,000 in Peru.

Sensitivity analysis: no CXR-CAD

If CXR-CAD were unavailable, the best alternative strategy would be entry, exit, and biannual
screening using Xpert on pooled sputum (**Table S5**). Compared to the next best strategy
(biannual screening with pooled Xpert), the combination of entry, exit, and biannual screening
with pooled Xpert had an ICER of $3607 in Brazil, $2551 in Colombia, and $642 in Peru. Other
strategies on the efficiency frontier included annual and biannual screening with symptoms or
pooled Xpert, depending on the country (**Figure S7**).

DISCUSSION

Evidence is lacking to guide optimal strategies for tuberculosis active case-finding in prisons. In
this study, we used a dynamic transmission model to project the population-wide impacts and
cost-effectiveness of different prison-based screening approaches in Brazil, Colombia, and Peru.
We find that combined entry, exit, and biannual screening with CXR-CAD is the most impactful
and cost-effective strategy in Brazil and Colombia, while a more sensitive algorithm (combining
symptoms and CXR-CAD) is justified in Peru's higher-burden prisons. These results support
prioritizing intensive, periodic prison-based screening up to twice yearly, particularly in settings
where prisons drive tuberculosis transmission.

The WHO recommends prison-wide screening at least annually and has stated that biannual mass
screening, while "ideal," may not be sustainable due to cost and logistical barriers[6,11]. As the first
modeling study to evaluate screening more than once a year, we found that biannual prison-wide
screening, alone or in combination with entry and exit screening, was highly cost-effective across
heterogeneous countries and led to substantial reductions in tuberculosis incidence in prisons and
in the general population. Importantly, these intensive strategies remained cost-effective at prison
incidence levels far below national averages, with biannual CXR-CAD alone remaining cost-
effective at levels as low as 200–400 per 100,000. These findings strongly support
implementation and regional scale-up of twice-yearly screening in prisons, with investments
justified by their projected population-wide benefits.

Regarding screening algorithms, strategies involving CXR-CAD were consistently the most
impactful and cost-effective, aligning with empirical studies demonstrating its feasibility and

cost-efficiency in prison settings[7,8,20-22]. Prior modeling work in other regions has also supported
the value of CXR-based screening in prisons[13,23]. In Brazil and Colombia, entry, exit, and
biannual screening with CXR-CAD alone was optimal. In Peru, where the model projected
prison incidence to exceed 5000 cases per 100,000 person-years without screening, combining
symptoms and CXR-CAD was cost-effective, reflecting a shift toward prioritizing sensitivity
over specificity. Of note, in 2023 the Peru National Tuberculosis Program (DPCTB) began
implementing entry and annual screening using this same algorithm, reaching nearly 40,000 PDL
across 18 prisons[8]. Overall, our results strongly support using CXR-CAD for systematic
screening in prisons. While implementation requires upfront investments in equipment, software,
and training, we accounted for these costs in our analysis, and CXR-CAD remained the cost-
effective algorithm. Moreover, advances in ultra-portable X-ray technology may further improve
scalability and sustainability of intensive periodic screening by enabling coverage of multiple
prisons with a single device[10].

In the absence of CXR-CAD, pooled Xpert was a favorable alternative, averting 87-92% as
many DALYs as CXR-CAD and remaining highly cost-effective across countries. While most
symptom-based strategies were dominated, intensive (i.e. biannual) symptom screening
nonetheless averted substantial DALYs—more than annual screening with CXR-CAD. These
findings highlight the importance of immediately implementing prison-wide screening with
available tools while developing capacity for more sensitive algorithms.

Entry or exit screening alone had modest impacts and should be performed in addition to
periodic prison-wide screening. Entry screening may integrate smoothly into prison intake
procedures but has lower yield per person screened due to the lower tuberculosis prevalence at
entry[12,24]. Exit screening also showed limited impact and may present substantial logistical
challenges under routine programmatic conditions. Nonetheless, given the high risk of
tuberculosis and barriers to continuity of care post-release, it remains a strategy worth exploring
in future work.

Notably, we project that if any screening intervention were to end without additional efforts to
reduce within-prison transmission, tuberculosis rates would rebound rapidly to pre-intervention
levels. To enable sustained progress toward tuberculosis elimination, intensive screening should
be paired with complementary interventions like tuberculosis preventive therapy, as well as
structural efforts to improve prison conditions and reduce incarceration rates[4,25,26].

There are several limitations to note. Our model did not include age, gender, or HIV, although
HIV prevalence is relatively low in these countries[27]. Our simplified approach to representing
MDR-TB does not capture complexities of longer treatment regimens or diagnostic delays,
which may influence preferred screening strategies. A study modeling tuberculosis screening in
prisons in the former Soviet Union, where MDR-TB rates are high, found that annual screening
with Xpert was more effective in reducing MDR-TB prevalence compared to annual
radiographic screening[23]. Pooled Xpert may be a useful tool in high MDR-TB prisons but should

be tested empirically. Furthermore, we did not explicitly model prison transfers, which could
reduce effectiveness if screening is not coordinated across facilities. This may partly explain the
discrepancy between our results and a recent empirical study in Brazil, which found no reduction
in tuberculosis prevalence after three rounds of prison mass screening between 2017 and 2021[28].
In that study, screening was limited to three of 29 male prisons in the state, and frequent transfers
likely diluted impact. Future work might examine how inter-facility movement and variation in
screening practices across facilities affect intervention effectiveness. Finally, we did not model
heterogeneity in infectiousness. If a small fraction of individuals accounts for most transmission,
imperfect screening coverage may allow continued transmission. Collectively, these factors
highlight the complexities of real-world implementation and the need for empirical studies to
validate and refine model projections and evaluate feasible strategies for operationalization under
programmatic conditions.

Altogether, our findings support the prioritization of combined entry, exit, and biannual
screening with CXR-CAD in Brazil, Colombia, and Peru, and similar settings. This strategy is
projected to be highly cost-effective and impactful in reducing tuberculosis morbidity and
transmission in prisons and population-wide. Screening should begin immediately with available
methods while infrastructure is developed for more impactful and cost-effective tools like CXR-
CAD. Ultimately, sustained investments in intensive, prison-wide screening—alongside
structural reforms to reduce incarceration and prison crowding—will be essential to advancing
regionally toward tuberculosis elimination.

Table 1. Accuracy and costs of screening interventions. Values listed are the mode (range)
from a triangle distribution or the median (range) when values are composites of individual
parameters. All costs are in 2023 US dollars (USD) and include consumable and personnel costs.
Listed costs of CXR-CAD alone and pooled Xpert also include costs of administering a symptom
interview. Follow-up testing includes clinical evaluation and Xpert Ultra. For Xpert pooling,
sensitivity is derived from the sensitivity of Xpert Ultra in a screening context, multiplied by the
relative sensitivity of using pooled samples. For costs of pooled Xpert, cartridge savings vary
based on TB prevalence; listed costs are the median (range) of costs over the ten-year
intervention horizon for annual screening. Additional intervention and cost parameters, including
costs of individual components, are provided in Table S1. CXR-CAD, chest x-ray with
computer-aided detection.

| | Sensitivity (%) | Specificity (%) | Per-unit cost (2023 USD) | | | Source |
			Brazil	Colombia	Peru	
Symptom screen	51 (30-70)	70 (60-80)	2.27 (2.00-3.00)	1.58 (1.39-2.08)	1.76 (1.50-2.50)	6,7,20,29,30
CXR-CAD	85 (75-88.5)	81 (70-93)	10.48 (8.28-13.60)	9.10 (7.40-11.48)	9.34 (7.24-12.19)	6,7,10,20
Symptoms & CXR-CAD	89 (84-93)	52 (41-63)	10.48 (8.28-13.60)	9.10 (7.40-11.48)	9.34 (7.24-12.19)	10,31
Pooled Xpert	66.1 (55.3-78.2)	98.8 (97-99.5)	19.38 (13.23-31.12)	14.01 (9.46-21.61)	15.62 (10.47-24.49)	32, 7,33, 34
Follow-up testing	90.9 (86.2-94.7)	98 (96-99.5)	26.43 (19.90-38.38)	21.93 (16.81-30.86)	23.50 (17.57-33.06)	34

Table 2. Costs, effects, and cost-effectiveness of strategies on the efficiency frontier. Mean estimates are shown, standardized per 100,000 population. All estimates are population-wide (i.e., they include costs and effects accrued by the entire population, not just those in prison). Costs are in 2023 US dollars (USD). Only strategies on the cost-effectiveness efficiency frontier are shown; all strategies are shown in **Table S3**. DALYs, disability-adjusted life years; increm, incremental; ICER, incremental cost-effectiveness ratio.

Strategy (intervention, algorithm)	Cost (USD)	Effect (DALYs averted)	Increm. cost	Increm. effect	ICER
Brazil					
Base case	304 676	0			
Annual, CXR-CAD	342 428	132	37 752	132	286
Biannual, CXR-CAD	385 659	208	43 231	76	565
Entry+exit+biannual, CXR-CAD	500 133	247	114 474	38	2984
Entry+exit+biannual, symptoms & CXR-CAD	660 055	257	159 922	10	15416
Colombia					
Base case	233 696	0			
Annual, CXR-CAD	256 909	120	23 213	120	193
Biannual, CXR-CAD	284 616	163	27 707	42	654
Entry+exit+biannual, CXR-CAD	320 799	175	36 183	12	2925
Entry+exit+biannual, symptoms & CXR-CAD	391 939	180	71 140	4	16207
Peru					
Base case	1 017 841	0	NA	NA	NA
Annual, CXR-CAD	1 045 096	426	27 254	426	64
Biannual, CXR-CAD	1 060 596	621	15 501	195	79
Entry+exit+biannual, CXR-CAD	1 098 123	679	37 526	58	645
Entry+exit+biannual, symptoms & CXR-CAD	1 203 201	704	105 078	25	4158

FIGURE LEGENDS

Figure 1. Impacts of screening interventions on within-prison and population-wide
tuberculosis incidence in 2035. CXR-CAD, chest X-ray with computer-aided detection.

Figure 2. Costs and cost-effectiveness of screening interventions. A) Mean additional cost of
screening interventions relative to the base-case scenario. The error bars indicate the 95%
uncertainty interval. B) Cost-effectiveness planes for each country. Strategies on the efficiency
frontier are highlighted. Costs are in 2023 USD. CXR-CAD, chest x-ray with computer-aided
detection; DALYs, disability-adjusted life years.

Figure 3. Optimal strategies under varying prison incidence scenarios. Prison incidence was
varied by varying the rate of within-prison transmission. The probability that a given strategy
was optimal across a range of prison incidence was modeled using multinomial logistic
regression. Only strategies with modeled probabilities greater than or equal to 5% in at least one
incidence quartile are shown; all other strategies are lumped into "other". Prison incidence under
approximately 300 per 100,000 was not modeled in Peru due to parameter constraints (see
Appendix, sensitivity analyses).

Funding Statement

This study was funded by the National Institutes of Health (grant numbers 5R01AI130058 and
5R01AI149620, awarded to JRA, https://www.niaid.nih.gov/). The funders were not involved in
study design, data collection and analysis, decision to publish, or preparation of the manuscript.
The content is solely the responsibility of the authors and does not necessarily represent the
official views of the National Institutes of Health.

References

1. WHO. Global tuberculosis report 2024. 2024.

2. Walter KS, Martinez L, Arakaki-Sanchez D, et al. The escalating tuberculosis crisis in central and South American prisons. *The Lancet* 2021; **397**(10284): 1591-6.

3. Martinez L, Warren JL, Harries AD, et al. Global, regional, and national estimates of tuberculosis incidence and case detection among incarcerated individuals from 2000 to 2019: a systematic analysis. *The Lancet Public Health* 2023; **8**(7): e511-e9.

4. Liu YE, Mabene Y, Camelo S, et al. Mass incarceration as a driver of the tuberculosis epidemic in Latin America and projected effects of policy alternatives: a mathematical modelling study. *The Lancet Public Health* 2024; **9**(11): e841-e51.

5. Charalambous S, Velen K, Rueda Z, et al. Scaling up evidence-based approaches to tuberculosis screening in prisons. *The Lancet Public Health* 2023; **8**(4): e305-e10.

6. World Health Organization. WHO Consolidated Guidelines on Tuberculosis. Module 2: Screening - Systematic Screening for Tuberculosis Disease, 2021.

7. Santos AdS, de Oliveira RD, Lemos EF, et al. Yield, Efficiency, and Costs of Mass Screening Algorithms for Tuberculosis in Brazilian Prisons. *Clinical Infectious Diseases* 2021; **72**(5): 771-7.

8. Jung E, Alarcón V, Solís Tupes WS, et al. National Active Case-Finding Program for Tuberculosis in Prisons, Peru, 2024. *Emerging Infectious Disease journal* 2025; **31**(3): 564.

9. Dos Santos PCP, da Silva Santos A, de Oliveira RD, et al. Pooling Sputum Samples for Efficient Mass Tuberculosis Screening in Prisons. *Clin Infect Dis* 2022; **74**(12): 2115-21.

10. Salindri AD BJ, Busatto C, da Silva AM, da Silva Santos A, Gonçalves IB, Gonçalves TO, Cunha EAT, Tsuha D, Lemos E, Oliveira RD, Croda M, Andrews JR, Croda J. Evaluation of an ultra-portable X-ray system with automated interpretation for tuberculosis active case finding in carceral: a diagnostic test accuracy study settings. *Research Square (PREPRINT)* 2025.

11. Dara M, Chorgoliani D, de Colombani P. TB prevention and control care in prisons: World Health Organization/Europe Health in Prisons Programme, 2014.

12. Mabud TS, de Lourdes Delgado Alves M, Ko AI, et al. Evaluating strategies for control of tuberculosis in prisons and prevention of spillover into communities: An observational and modeling study from Brazil. *PLOS Medicine* 2019; **16**(1): e1002737.

13. Legrand J, Sanchez A, Le Pont F, Camacho L, Larouze B. Modeling the impact of tuberculosis control strategies in highly endemic overcrowded prisons. *PLoS One* 2008; **3**(5): e2100.

14. Menzies NA, Quaife M, Allwood BW, et al. Lifetime burden of disease due to incident tuberculosis: a global reappraisal including post-tuberculosis sequelae. *The Lancet Global Health* 2021; **9**(12): e1679-e87.

15. World Bank. GDP deflator (base year varies by country). 2023.

16. Sanders GD, Neumann PJ, Basu A, et al. Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. *Jama* 2016; **316**(10): 1093-103.

17. Ministerio de Salud DGdM, Insumos y Drogas,. Estimación del umbral costo - efectividad para las evaluaciones económicas en salud. Informe técnico. Perú, 2022.

18. Ministério da Saúde. O uso de limiares de custo-efetividade nas decisões em saúde: recomendações da Comissão Nacional de Incorporação de Tecnologias no SUS. In: Secretaria de Ciência T, Inovação e Insumos Estratégicos em Saúde; Departamento de Gestão e Incorporação de Tecnologias em Saúde, editor. Brasilia/DF, Brazil; 2022.

19.   Espinosa O, Rodríguez-Lesmes P, Orozco L, et al. Estimating cost-effectiveness
thresholds under a managed healthcare system: experiences from Colombia. *Health Policy and*
Planning 2022; **37**(3): 359-68.
20.   Soares TR, Oliveira RDd, Liu YE, et al. Evaluation of chest X-ray with automated
interpretation algorithms for mass tuberculosis screening in prisons: a cross-sectional study. *The*
Lancet Regional Health - Americas 2023; **17**: 100388.
21.   Machekera SM, Wilkinson E, Hinderaker SG, et al. A comparison of the yield and
relative cost of active tuberculosis case-finding algorithms in Zimbabwe. *Public Health Action*
2019; **9**(2): 63-8.
22.   Smit GSA, Apers L, Arrazola de Onate W, et al. Cost–effectiveness of screening for
active cases of tuberculosis in Flanders, Belgium. *Bulletin of the World Health Organization*
2017; **95**(1): 27-35.
23.   Winetsky DE, Negoescu DM, DeMarchis EH, et al. Screening and rapid molecular
diagnosis of tuberculosis in prisons in Russia and Eastern Europe: a cost-effectiveness analysis.
PLoS Med 2012; **9**(11): e1001348.
24.   Sequera G, Estigarribia-Sanabria G, Aguirre S, et al. Excess tuberculosis risk during and
following incarceration in Paraguay: a retrospective cohort study. *The Lancet Regional Health –*
Americas.
25.   Urrego J, Ko AI, da Silva Santos Carbone A, et al. The Impact of Ventilation and Early
Diagnosis on Tuberculosis Transmission in Brazilian Prisons. *Am J Trop Med Hyg* 2015; **93**(4):
739-46.
26.   Narayan A, Salindri AD, Keshavjee S, et al. Prioritizing persons deprived of liberty in
global guidelines for tuberculosis preventive treatment. *PLoS Med* 2023; **20**(10): e1004288.
27.   García PJ, Bayer A, Cárcamo CP. The changing face of HIV in Latin America and the
Caribbean. *Curr HIV/AIDS Rep* 2014; **11**(2): 146-57.
28.   Pivetta de Araujo RC, Martinez L, da Silva Santos A, et al. Serial Mass Screening for
Tuberculosis Among Incarcerated Persons in Brazil. *Clin Infect Dis* 2024; **78**(6): 1669-76.
29.   Pelissari DM, Kuhleis DC, Bartholomay P, et al. Prevalence and screening of active
tuberculosis in a prison in the South of Brazil. *Int J Tuberc Lung Dis* 2018; **22**(10): 1166-71.
30.   Telisinghe L, Fielding KL, Malden JL, et al. High Tuberculosis Prevalence in a South
African Prison: The Need for Routine Tuberculosis Screening. *PLOS ONE* 2014; **9**(1): e87262.
31.   van't Hoog A, Viney K, Biermann O, Yang B, Leeflang MMG, Langendam MW.
Symptom‐ and chest‐radiography screening for active pulmonary tuberculosis in HIV‐
negative adults and adults with unknown HIV status. *Cochrane Database of Systematic Reviews*
2022; (3).
32.   dos Santos PCP, da Silva Santos A, de Oliveira RD, et al. Pooling Sputum Samples for
Efficient Mass Tuberculosis Screening in Prisons. *Clinical Infectious Diseases* 2021.
33.   Shapiro AE, Ross JM, Yao M, et al. Xpert MTB/RIF and Xpert Ultra assays for screening
for pulmonary tuberculosis and rifampicin resistance in adults, irrespective of signs or symptoms.
Cochrane Database of Systematic Reviews 2021; (3).
34.   Zifodya JS, Kreniske JS, Schiller I, et al. Xpert Ultra versus Xpert MTB/RIF for
pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary
tuberculosis. *Cochrane Database of Systematic Reviews* 2021; (2).